About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify
16 December 2019
Scientific Clinical | Nanobiotix announces Fast Track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in Head and Neck cancer
10 February 2020
Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Published by
Julie Ficheux
on
7 January 2020
No translations available for this page
